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Background: Considerable clinical heterogeneity has been well documented amongst individuals with autism
spectrum disorders (ASD). However, little is known about the biological mechanisms underlying phenotypic
diversity. Genetic studies have established a strong causal relationship between ASD and molecular defects in the
SHANK3 gene. Individuals with various defects of SHANK3 display considerable clinical heterogeneity. Different lines
of Shank3 mutant mice with deletions of different portions of coding exons have been reported recently. Variable
synaptic and behavioral phenotypes have been reported in these mice, which makes the interpretations for these
data complicated without the full knowledge of the complexity of the Shank3 transcript structure.
Methods: We systematically examined alternative splicing and isoform-specific expression of Shank3 across different
brain regions and developmental stages by regular RT-PCR, quantitative real time RT-PCR (q-PCR), and western blot.
With these techniques, we also investigated the effects of neuronal activity and epigenetic modulation on
alternative splicing and isoform-specific expression of Shank3. We explored the localization and influence on
dendritic spine development of different Shank3 isoforms in cultured hippocampal neurons by cellular imaging.
Results: The Shank3 gene displayed an extensive array of mRNA and protein isoforms resulting from the
combination of multiple intragenic promoters and extensive alternative splicing of coding exons in the mouse
brain. The isoform-specific expression and alternative splicing of Shank3 were brain-region/cell-type specific,
developmentally regulated, activity-dependent, and involved epigenetic regulation. Different subcellular distribution
and differential effects on dendritic spine morphology were observed for different Shank3 isoforms.
Conclusions: Our results indicate a complex transcriptional regulation of Shank3 in mouse brains. Our analysis of
select Shank3 isoforms in cultured neurons suggests that different Shank3 isoforms have distinct functions.
Therefore, the different types of SHANK3 mutations found in patients with ASD and different exonic deletions of
Shank3 in mutant mice are predicted to disrupt selective isoforms and result in distinct dysfunctions at the synapse
with possible differential effects on behavior. Our comprehensive data on Shank3 transcriptional regulation thus
provides an essential molecular framework to understand the phenotypic diversity in SHANK3 causing ASD and
Shank3 mutant mice.
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Shank3/ProSAP2 is one of three members of the
Shank/ProSAP family of proteins which contain five
conserved protein domains – an ankyrin repeat (ANK),
a Src homology 3 (SH3), a PSD-95/Discs large/ZO-1
(PDZ), a proline-rich region containing homer- and
cortactin-binding sites (Pro), and a sterile alpha motif
(SAM) [1-3]. Shank proteins localize in the postsynaptic
density (PSD) of excitatory synapses where they function
as master scaffolding proteins by interacting directly or in-
directly with various proteins, including major types of
glutamate receptors – NMDARs, AMPARs, and mGluRs –
via different domains [1,2,4-8].
Human genetic studies strongly support the notion
that molecular defects of SHANK3 contribute to autism
spectrum disorders (ASD). In humans, SHANK3 maps
to the critical region of the 22q13.3 deletion syndrome
(Phelan-McDermid syndrome; PMS), in which autistic
behaviors are an important feature [9]. In addition, de
novo sequence variants including missense, frame-shift,
and splice site mutations across all coding exons of
SHANK3 have been identified in ~0.5% of ASD patients
with variable clinical presentations [10-14]. Interestingly,
SHANK3 mutations were also reported in patients with
childhood-onset schizophrenia and intellectual disability
[15]. In the cases with point mutations or small deletions
of SHANK3, it was noted that clinical features are also
quite variable [8]. Shank3 mutant mice with deletions
of exons encoding ANK, SH3, and PDZ domains and
proline-rich region have been reported [16-20]. These
mutant mice shared some similarities but also have sig-
nificant differences in synaptic defects and behavioral
abnormalities. The interpretations for the data from dif-
ferent lines of mutant mice were complicated at the time
by the lack of clear understanding of the complexity of
Shank3 transcript structure. It was believed that differ-
ent lines of mutant mice only disrupted a select set of
Shank3 isoforms. These observations then demand more
knowledge of transcriptional regulation of Shank3 in the
brain, and pose an interesting question about the mo-
lecular basis underlying the clinical heterogeneity in hu-
man patients with SHANK3 defects and the variability in
different Shank3 mutant mice.
SHANK3 undergoes complex transcriptional regulation
[8,21-24]. We and others have determined that Shank3
displays multiple intragenic promoters and alternative
splicing of coding exons in both mice and humans
[12,18,23,25,26]. The combination of multiple promoters
and alternative splicing is predicted to produce an exten-
sive array of mRNA and protein isoforms, but this has not
been fully characterized. With the information of pre-
sumptive SHANK3 isoforms, point mutations or small ex-
onic deletions of SHANK3 found in ASD patients are
predicted to affect selective isoforms of SHANK3. Sinceeach SHANK3 isoform contains a distinct combination of
the five different protein-protein interaction domains,
each isoform may have a different function at the synapse.
One interesting hypothesis is that isoform-specific disrup-
tions by point mutations and small intragenic deletions
within the SHANK3 gene contribute to the clinical hetero-
geneity in humans and variable phenotypes seen in mice.
As a first step to test this hypothesis, we conducted a
series of experiments to systematically characterize the
extent and regulation of isoform-specific expression of
Shank3 in mice because of the ready availability of brain
tissues and amenability of this model species to experi-
mental manipulation. We discovered that Shank3 under-
goes extensive alternative splicing in the exons encoding
for conserved protein domains. We report, for the first
time, that the expression and alternative splicing of
Shank3 isoforms are brain-region and developmentally
specific, activity dependent, and involve epigenetic regu-
lation. We also found that different Shank3 isoforms dis-
played different subcellular distribution and differential
effects on dendritic spine morphology, suggesting a dif-
ferent function for each isoform. We propose that iso-
form diversity of Shank3 is one of the explanations for




All experiments in animals were conducted with ap-
proved protocols by the Institutional Animal Care and
Use Committee at Duke University.
Primary neuron culture and drug treatments
The methods for primary hippocampal and cortical
neuron cultures were described previously [18]. Briefly,
hippocampal and cortical tissues were dissected from
newborn C57BL/6J pups between postnatal day 0 and
day 1, and digested with trypsin. Tissues were pelleted
by brief centrifugation and then dissociated in Neurobasal/
B27 medium. Cells were plated into 60 mm dishes coated
with 0.1 mg/mL poly-D-lysine at a density of 4 × 106 cells/
dish. Cells were treated on 8–10 days in vitro with either
30 mM KCl or 5 μM trichostatin A (TSA) for 16 hours.
Astrocyte monolayers were derived from the hippocampus
of postnatal day 7 C57BL/6J mice as described [27]. Total
RNA and protein were prepared for quantitative PCR or
western blot analysis.
DNA constructs and transfection
Mouse brain cDNAs were prepared from cerebral cortex
of 8-week-old mice. Specific primers for Shank3 isoforms
(3a, 3b, 3c, and 3e) were employed to amplify PCR prod-
ucts containing the complete open reading frame of each
isoform, and the PCR products were cloned into EGFP-C1
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USA). COS-7 cells growing on coverslips in 6-well plates
were transfected with 2 μg of different Shank3 constructs
using FuGENE HD transfection reagent (Promega, WI,
USA) according to the manufacturer’s technical manual.
The cells were fixed by 4% paraformaldehyde 36 hours
post-transfection. Dissociated hippocampal neurons were
grown on poly-D-lysine-coated coverslips. After 7 days
in vitro, neurons were transfected with Shank3 constructs
using Lipofectamine 2000 transfection reagent (Invitrogen,
CA, USA). Briefly, on the day of transfection, half of the
medium was removed from each well and kept at 4°C.
DNA and Lipofectamine 2000 were mixed in serum-free
neurobasal medium with a ratio 1:3 (μg:μL). The mixture
was added into each well and incubated for 6 hours be-
fore replacement with the previously saved conditioned
medium. The cells were fixed by 4% paraformaldehyde
after 14 days in vitro. To analyze the spine morphology,
neurons were co-transfected with Shank3 constructs
and a tdTomato plasmid.
Immunochemistry and morphology analysis of dendritic
spines
Fixed neurons were permeabilized with 0.2% triton-X 100
in 1× phosphate buffered saline (PBS), blocked with 2%
bovine serum albumin, and co-stained with rabbit anti-
GFP (Invitrogen) and mouse anti-PSD-95 (UC Davis/NIH
NeuroMab Facility) antibodies and corresponding second-
ary antibodies conjugated with Alexa 488 or Alexa 568.
Confocal images were obtained using a 63× objective
(Zeiss LSM 510 inverted) with sequential acquisition set-
tings of 1024 × 1024 pixels. Each image was a z-series pro-
jection of 3–4 images at 0.5-μm depth intervals and
averaged four times. Morphometric analysis and quantifi-
cation of PSD-95 and dendritic spines were performed
using Image J software (NIH, Bethesda, MD, USA) by an
experimenter who was blinded to experiment conditions.
RNA isolation and RT-PCR expression analysis
Tissues from different brain regions were dissected from
coronal sections of brain slices cut by a Leica VT 1000p
microtome (Leica, IL, USA). Total RNA was isolated using
the TRIzol method (Life Technologies, CA, USA). Reverse
transcription was performed with SuperScript® III first-
strand synthesis system (Invitrogen). Real-time quantita-
tive RT-PCR (q-PCR) was carried out using a LightCycler
480 Instrument (Roche Diagnostics, Mannheim, Germany)
and QuantiFast SYBR green PCR kit (Qiagen, CA, USA),
following the manufacturer’s recommendations. The pri-
mers used in this study are listed in Additional file 1:
Table S1. AccuPrime GC-Rich DNA Polymerase (Invitro-
gen) was employed to amplify the full-length GC-rich se-
quence of exons 10–12 of Shank3. The sequences of newly
identified splice variants were annotated and deposited inGenbank. Quantification of the bands of splicing variants
were carried out using Image J [28].
Western blot
Western blot was performed as previously described [29].
Briefly, brain tissues were homogenized and sonicated in
modified RIPA buffer (1× PBS, 1% Triton X-100, 0.1%
SDS, 2 mM EDTA, and protease inhibitors); 25 μg of
proteins were resolved by PAGE and transferred onto
polyvinylidene difluoride (PVDF) membranes. The PVDF
membranes were blocked with 5% milk and incubated
with Shank3 (1:5,000 in 5% non-fat milk) antibody
(sc-30193, Santa Cruz, Dallas, TX, USA) at 4°C over-
night. Following incubation with horseradish peroxidase-
conjugated secondary antibody, the membranes were
incubated with a Pierce chemiluminescent substrate
(Rockford, IL, USA) and exposed to X-ray film.
Results
Multiple protein isoforms produced by intragenic
promoters in mouse brain
The mouse Shank3 gene has 22 exons that encode a
synaptic scaffolding protein with five functional do-
mains (Figure 1A). We have previously demonstrated
that the Shank3 gene contains at least five intragenic
promoters in humans and rodents which produce
promoter-specific isoforms of Shank3 with various com-
binations of different functional domains [8,18,25] as
summarized in Figure 1E. The presence of multiple in-
tragenic promoters is supported by CHIP sequencing
data from the ENCODE project (Additional file 2:
Figure S1B, http://genomebrowser.wustl.edu). The analysis
of ENCODE data also suggests that these intragenic pro-
moters are brain specific, which was confirmed by western
blot analysis of Shank3 protein among different tissues
(Additional file 2: Figure S1C). The presence of intragenic
promoters in vivo is also supported by the expression
analysis in a list of Shank3 isoform-specific mutant mice.
In these mutant mice, different portions of Shank3 exons
were deleted, resulting in disruption of select sets of
Shank3 proteins and mRNAs [16-20]. In support of these
findings, Shank3 complete knockout mice with deletion of
exons 4–22 showed absence of all known promoter-
specific isoforms (data not shown).
Extensive alternative splicing of Shank3 mRNAs confers
further complexity to Shank3 isoforms
Alternative splicing of Shank3 has been suggested [12,18]
but has not been fully characterized. We conducted RT-
PCR with primer combinations that cover all exons of
Shank3 (Additional file 2: Figure S1A) using total RNA
from the cerebral cortex of 8-week-old mice. We discov-
ered that the coding exons 10–12, exon 18, exon 21, and
exon 22 of Shank3 displayed extensive alternative splicing
Figure 1 Diverse Shank3 isoforms result from intragenic promoters and alternative splicing. (A) Multiple promoters of the Shank3 gene.
Mouse Shank3 has 22 coding exons as illustrated. The exon-intron structure was deduced by cDNA AB231013 in mm10 mouse genome assembly
(www.genome.ucsc.edu). The alternatively spliced exons are highlighted in red. The positions of intragenic promoters are shown as black arrows.
Protein domains encoded by exons are labeled above the gene structure. (B–D) Extensive alternative splicing of Shank3 coding exons. (B) Shank3
exons 10–12 splice variants (E10–12S I to V). The pattern was deduced from the sequences of PCR products in Figure S2A (Additional file 3). I:
no splicing. II: exon 11 partially spliced out. III: exon 11 spliced out. IV: exons 11 to 12 spliced out. V: exons 10 to 12 spliced out. (C) Shank3e
splice variants (E18S I to V). The pattern was deduced from the sequences of PCR products in Figure S2C (Additional file 3). I: no splicing. II: exon
18 spliced out. III: exons 18, 21, and 22 (partial) spliced out. IV: exons 18 to 21 and 22 (partial) spliced out. (D) Shank3 exon 21 and exon 22 splice
variants (E21–22S I to IV). The pattern was deduced from the sequences of PCR products in Figure S2E (Additional file 3). I: no splicing. II: exon 22
(partial) spliced out. III: exon 21 spliced out. IV: exon 21 and exon 22 (partial) spliced out. (E) The predicted Shank3 protein isoforms were deduced
from the combination of intragenic promoters and alternative splicing of mRNAs described above and in silico analysis. The binding positions of
several well-known PSD proteins are shown by arrows. The epitope position for the Shank3 antibody used in this study is also indicated.
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tively spliced exons were concentrated in the conserved
SH3, proline-rich, and SAM domains of Shank3 and re-
sulted in protein species with different combinations of
the five functional domains. The alterative splicing of
exons 10–12 resulted in five different splice variants
(E10–12S I to V, Figure 1B). E10–12S I represented the
full length of this portion of mRNA without alternativesplicing. In E10–12S II, a cryptic splicing of 57 nucleotides
occurred in exon 11 without a shift of the open reading
frame (ORF) of Shank3 mRNA. However, splice variants
of E10–12S III and IV resulted in truncated isoforms only
containing the ANK domain due to a frame shift of the
Shank3 ORF (Figure 1E). Interestingly, skipping of exons
10 to 12 in E10–12S V was predicted to produce a Shank3
isoform without the SH3 domain but presumably retaining
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splicing of exons 18–22 was examined by primers specific
to promoter 5 for Shank3e (Additional file 2: Figure S1A).
Four splice variants (E18S I to IV, Figure 1C) were identi-
fied. Exon 18 was spliced out in E18S II to IV. The splicing
of exon 18 appeared to be in concert with splicing of
exons 21/22 or exons 19–22 in Shank3 E18S III and IV,
respectively. The frame shift of the Shank3 ORF in E18S
III and IV variants is predicted to result in premature stop
codons in exon 22 and produced short Shank3e isoforms
(Shank3e-1) lacking the proline-rich region and SAM
domain (Figure 1E). With a different set of primers, al-
ternative splicing of exons 21 and 22 was examined, and
four different variants were observed (E21–22S I to IV,
Figure 1D). While the E21–22S I and II variants did not
change the ORF of Shank3, the E21–22S III and IV variants
were predicted to produce C-terminal truncated Shank3
isoforms lacking the SAM domain due to premature stop
codons in exon 22. In summary, these results indicate that
Shank3 undergoes extensive alternative splicing, which re-
sults in extreme diversity of Shank3 isoforms at mRNA
and possibly at protein levels.
Region- and development-specific expression of Shank3
isoforms in mouse brain
Regional and developmental expression of Shank3 has
been previously examined by RNA in situ hybridization
[17,30]. However, the probes used in these studies could
not distinguish between different Shank3 isoforms. To
examine the isoform-specific expression of Shank3 in
different brain regions, we performed isoform-specific
q-PCR using 8-week-old mice (Figure 2A–E). Shank3a
and Shank3e were highly expressed in striatum but low
in olfactory bulb and cerebellum. In contrast, Shank3c
and Shank3d were predominantly enriched in cerebel-
lum. Shank3b, an isoform without exon 21 encoding the
homer binding site, is expressed at low levels throughout
the brain. We were not able to design primers to exam-
ine mRNA from Shank3f because this promoter is em-
bedded within exon 21. Western blot analysis using an
antibody against the C-terminus of Shank3 revealed an
expression pattern that is highly correlated with the pat-
tern of q-PCR (Figure 2F). Specifically, Shank3a and
Shank3e were predominant in striatum and Shank3c/d
was exclusively enriched in the cerebellum. Parenthetic-
ally, the diversity of Shank3 protein products may be
under-represented because some truncated Shank3 pro-
tein isoforms are not detectable due to the location of
the epitope of the Shank3 antibody used. Developmental
expression of Shank3 was also examined by q-PCR using
whole brains from mice of different ages (Figure 2G–K),
and all isoforms showed an increase from postnatal day 1
to 4 weeks. The peak of expression was between 2 and
4 weeks, correlating with the time frame for synaptogenesis.Shank3a and Shank3e displayed a gradual decrease after
4 weeks and reduced to 50% of the peak level at 12 months
of age. In contrast, the expression of Shank3c and Shank3d
was relatively stable throughout adulthood. Western blot
revealed a similar pattern of Shank3 protein isoforms at dif-
ferent postnatal ages in mouse brain (Figure 2L). The tem-
porally and spatially specific expression of Shank3 isoforms
suggests different functions for different isoforms.
Region-, development-, and cell-type-specific alternative
splicing of Shank3 isoforms in mouse brain
We next investigated whether alternative splicing of
Shank3 isoforms also displays a temporally and spatially
specific pattern in mouse brains. In the adult brain, the
splicing of E10–12S III to IV showed a higher rate in the
olfactory bulb and thalamus as compared to other re-
gions (Figure 3A, B). The splicing of E18S II variants
displayed a similar pattern (Figure 3A, C). During devel-
opment, the splice variants E10–12S III and E18S II
were prominent at postnatal day 1, then rapidly de-
creased at postnatal day 5 and only expressed at mar-
ginal levels after postnatal day 10 (Figure 3D, E). The
ratio of exon 18– (E18S II) versus exon 18+ (E18S I) was
inverted from postnatal day 1 to postnatal day 5
(Figure 3F). The expression of E10–12S V significantly
increased toward 4 weeks and decreased in the adult
brain (Figure 3D). The splice variants of E18S III and IV
were also differentially regulated during development. In
addition, alternative splicing of Shank3 isoforms also
displayed a cell-type-specific pattern (Additional file 4:
Figure S3). Interestingly, alternative splicing of exon 18
was mutually exclusive between cell types, with exon 18
inclusion (E18S I) in neurons and exon18 exclusion
(E18S II) in astrocytes. Similarly, the E18S III variant
was exclusively observed in neurons while E18S IV was
only found in astrocytes. Taken together, these results
showed that alternative splicing of Shank3 is region-,
development-, and cell-type-specific.
Activity dependent expression and alterative splicing of
Shank3
The expression of many neuronal genes is regulated by
neuronal activity [31,32]. To investigate if the splicing
and expression of Shank3 are also regulated by neuronal
activity, we treated cultured hippocampal neurons with
KCl. At the mRNA level, the expression of Shank3a, 3c,
3d, and 3e in stimulated neurons was reduced to 40% to
70% of controls while the expression of Shank3b was not
affected (Figure 4A). Similarly, Shank3 protein isoforms
were markedly reduced after KCl treatment (~20% of
controls) (Figure 4B, C). The reduction of Shank3 pro-
tein after KCl treatment was more pronounced than that
of Shank3 mRNAs. The reason underlying the difference
between the mRNAs and proteins was not immediately
Figure 2 Differential expression of Shank3 isoforms across brain regions and development. (A–E) q-PCR of Shank3 major isoforms in
different brain regions. (G–K) q-PCR of Shank3 isoforms in brain across development. The crossing point (CP) values of each isoform were
normalized to that of a housekeeping gene, Rpl13a. For brain regions: OB, olfactory bulb; CX, cortex; ST, striatum; HP, hippocampus; TH, thalamus;
AD, amygdala; CB, cerebellum. For different ages: P1, postnatal day 1; P5, postnatal day 5; P10, postnatal day 10; P15, postnatal day 15; 4 W,
4 weeks; 3 M, 3 months; 12 M, 12 months. (F and L) Western blot analysis using an antibody produced from an epitope at the C-terminus of
SHANK3 protein (amino acids 1431 to 1590) for different mouse brain regions (F) or at different ages (L). The predicted bands for Shank3a
(185KD), Shank3c/d (128KD/127KD), and Shank3e (118KD) are indicated by arrows. All of these bands migrate a little higher than prediction, which
may be caused by post-translational modifications of Shank3 proteins. Shank3b was not detectable as the epitope of the antibody was spliced
out in this isoform. All data are shown as mean ± SEM.
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Shank3 protein may be considered. For example, ubiqui-
tin/proteasome-mediated protein degradation of Shank
family proteins following neuronal activity has been ob-
served [31]. Alternative splicing of Shank3 was also af-
fected by KCl treatment (Figure 4D). A significant increase
in the splice variants E10–12S III to IV, E18S II, and E18S
IV was observed after KCl treatment (Figure 4E–G). In
contrast, the splice variants E21–22S were not affected
(data not shown). These results indicate that the expres-
sion and alternative splicing of Shank3 isoforms are regu-
lated by neuronal activity.Expression and alternative splicing of Shank3 are
regulated by a histone deacetylase (HDAC) inhibitor
Epigenetic modifications, such as histone acetylation, have
been shown to regulate expression and alternative splicing
of neuronal genes [33,34]. To examine whether expression
and alternative splicing of Shank3 are subject to epigenetic
regulation, we treated hippocampal neurons with TSA,
a potent HDAC inhibitor. Interestingly, TSA treatment
exerted differential effects on the isoform-specific expres-
sion of Shank3. At the mRNA level, Shank3a and Shank3e
were significantly reduced while Shank3c and Shank3d
were markedly increased (Figure 5A). The expression of
Figure 3 Alternative splicing of Shank3 in different brain regions and across development. (A) Splicing of Shank3 coding exons in
different brain regions. (B) Quantification for splicing of E10–12S III to IV in (A). The values of the spliced bands were normalized to E10–12S I
without splicing. (C) Quantification for splicing of exon 18 in (A). Values were shown as the ratio of exon18 (−) to exon18 (+). (D) Splicing of
Shank3 coding exons during brain development. (E) Quantification for splicing of E10–12S III in (D), values of the spliced products were
normalized to that of E10–12S I without splicing. (F) Quantification for splicing of exon 18 of Shank3e in (D). All data are shown as mean ± SEM.
The abbreviations for different brain regions and ages are the same as in Figure 2.
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was also supported by the overall reduction of Shank3
proteins (Figure 5B, C). However, isoform-specific changes
were not apparent by western blot analysis. The discrep-
ancy between the mRNA and protein expression is not
immediately clear. The possibility of antibody specificity
and sensitivity may be considered. Alternatively, the in-
volvement of protein modification for different protein
isoforms related to HDACs may also be a factor. TSA
treatment also induced an increase in E10–12S III to IVand a reduction of E18S IV (Figure 5D, E, G). Splicing of
E18S II was not changed despite a marked decrease of
Shank3e mRNA (Figure 5D, F). Alternative splicing of
Shank3 E21–22 was not affected by TSA treatment (data
not shown). Taken together, the expression and splicing of
Shank3 isoforms were differentially regulated by an HDAC
inhibitor, suggesting the involvement of epigenetic modifi-
cations in regulating Shank3 expression, but the exact
mechanisms are not immediately clear and further investi-
gation is warranted.
Figure 4 Neuronal activity-dependent isoform-specific expression and alternative splicing of Shank3. (A) q-PCR analysis of Shank3
isoforms in cultured mouse cortical neurons after treatment with 30 mM KCl for 18 hours. The expression of Shank3a, 3c, 3d, and 3e was
significantly reduced while no change was observed for Shank3b. (B) Western blot showed reduced Shank3 proteins after KCl treatment.
(C) Quantification for Shank3 proteins in (B). (D) Splicing of Shank3 isoforms after KCl treatment. Alternative splicing for E10-12S III-IV (E), E18S II
of Shank3e (F), and E18S IV of Shank3e-1 (G) were increased after KCl treatment. All data are shown as mean ± SEM. *P <0.05, #P <0.002,
^P <0.001, compared to control group, two tail t-test, n = 4 each group.
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and their effects on dendritic spines
To analyze the subcellular distribution of Shank3 iso-
forms and their roles in regulation of dendritic spines,
we cloned cDNAs of major Shank3 isoforms into EGFP-
C1 vectors. First, we overexpressed these constructs in
COS-7 cells (Additional file 5: Figure S4A). As a control,
GFP showed a diffuse pattern without cluster formation,
while Shank3a, c, and e, all containing the proline-rich
region and SAM domain, formed clusters in the cyto-
plasm. Overexpression of Shank3 exon 22 only encoding
the SAM domain displayed a similar pattern, indicating
the clusters were mediated by the SAM domain through
homo-/hetero-polymerization [1]. Interestingly, Shank3b
was localized in the nucleus as it overlapped with DAPI,
a nucleus-staining marker. This suggests that the lack
of proline-rich and SAM domains may be responsible for
its nuclear targeting. The nuclear localization of Shank3b
was also verified when it was expressed in cultured
hippocampal neurons (Additional file 5: Figure S4B). Todetermine whether any Shank3 isoform is present in
inhibitory synapses or not, we examined the overlap of
Shank3 isoforms with gephyrin, an inhibitory post-synaptic
marker. None of the Shank3 isoforms examined localized
in inhibitory synapses of cultured neurons (Additional
file 6: Figure S5). However, it remains to be investigated
whether the same is true in vivo in mouse brain due to the
technical caveats of cultured cells. The co-localization of
PSD-95, a marker of excitatory post-synapses, with Shank3a
and Shank3c was observed in dissociated hippocampal
neurons but was not apparent with Shank3b and Shank3e
(Figure 6A). The size and the density of PSD-95 puncta
were increased in Shank3a transfected neurons, indicating
an increase in excitatory synapses. On the contrary, overex-
pression of Shank3b and Shank3e resulted in a reduction of
the size and density of PSD-95 (Figure 6B, C). We further
examined the contribution of different Shank3 isoforms
in dendritic spine development by co-transfection of
Shank3 isoforms and tdTomato in hippocampal neu-
rons (Figure 6D). Shank3a and Shank3c caused an
Figure 5 Differential isoform-specific expression and alternative splicing of Shank3 induced by a histone deacetylase (HDAC)
inhibitor. (A) q-PCR analysis of Shank3 isoforms in cultured mouse cortical neurons after treatment with 5 μM trichostatin A (TSA), a potent
HDAC inhibitor, for 18 hours. (B) Western blot showed reduced Shank3 proteins after TSA treatment. (C) Quantification for Shank3 proteins
in (B). (D) Differential changes of alternative splicing of Shank3 after TSA treatment. (E) Alternative splicing for Shank3 E10–12S III to IV was
increased. (F) Splicing for E18S II of Shank3e was not changed. (G) Splicing for E18S IV of Shank3e-1 was decreased. All data are shown as
mean ± SEM. * P <0.05, # P <0.002, compared to the control group, two tail t-test, n = 4 each group.
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length compared to the EGFP control. Shank3b and
Shank3e did not cause significant changes in the spine
density (P = 0.47 and 0.97, respectively) but resulted in a
marked increase in spine length (Figure 6E, F), indi-
cating the formation of more immature synapses. These
results indicate that Shank3 isoforms have different sub-
cellular localization and differential effects on dendritic
spine development, further suggesting that they play
different roles in the brain.
Discussion
Using various molecular genetics approaches, we have de-
scribed an unusually complex transcriptional profile for
Shank3, a strong human autism causative gene, in the
mouse brain. We have delineated transcript structures for
major Shank3 isoforms resulting from the combination of
multiple intragenic promoters and alternative splicing. Fur-
thermore, we showed, for the first time, that the isoform-
specific expression of Shank3 is temporally and spatially
specific and regulated by neural activity. We showed
that the isoform-specific expression of Shank3 in cortical
neurons involves an epigenetic regulation suggested inprevious reports [23,35]. Further, this is the first report in-
dicating that a selective Shank3 isoform is strictly localized
in neuronal nuclei which implies a novel function other
than as a scaffolding protein at the PSD. Our results sup-
port the hypothesis that different Shank3 isoforms have
distinct functions at synapses. These findings will promote
our knowledge of the molecular diversity in the brain
and help us to understand the phenotypic heterogeneity
caused by various SHANK3 defects in humans and mice.
The implication of molecular complexity of Shank3 to the
functional diversity of synapses
Our results reveal that Shank3 displays more isoforms in
the brain than it does in peripheral tissues and suggest
that each Shank3 isoform has a unique function, which
allows us to propose that the complexity of Shank3 con-
tributes to the functional diversity of synapses. First, the
major isoforms of Shank3 generated from different pro-
moters contain distinct combinations of the five con-
served domains, which provide the functional diversity
for Shank3 isoforms. The full-length Shank3a contains
all five domains which would have the capacity to inter-
act with all possible interacting proteins. Other isoforms
Figure 6 Differential contributions of Shank3 isoforms to excitatory synapses. (A) Co-localization of Shank3 isoforms with PSD-95. Shank3
isoforms tagged with GFP (green) were expressed in primary hippocampal neurons and co-stained with an excitatory post-synaptic marker
PSD-95 (red). Shank3 isoforms displayed differential impacts on the size (B) and density (C) of PSD-95 puncta. (D) Impacts of Shank3 isoforms on
dendritic spine morphology. EGFP-Shank3 isoforms (green) were co-transfected with tdTomato (red) in hippocampal neurons. Shank3 isoforms
displayed differential effects on spine density (E) and spine length (F) of hippocampal neurons. All data are shown as mean ± SEM. *, P <0.01,
compared to GFP; #, P <0.01, compared to Shank3a, two tail t-test. Scale bar: 10 μm.
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then interact with a different subset of synaptic proteins.
For instance, the N-terminal truncated Shank3e only con-
tains the proline-rich region and SAM domain and would
be able to couple with homer-mGluRs complexes but not
GKAP-PSD95-NMDARs complexes [4,5]. In contrast, the
C-terminal truncated Shank3b would be able to interact
with NMDARs but not mGluRs. By competing with
Shank3a, one of the functions of Shank3b and Shank3e
might be the regulation of the cross-talk between NMDARs
and mGluRs, which results in the fine tuning of synaptic
transmission. Second, alternative splicing contributes to
further complexity of Shank3 isoforms and functional di-
versity. Alterative splicing of Shank3 is predicted to have an
impact on the function of Shank3 since it is heavily concen-
trated in the exons encoding functional protein domains.
The splice variants of E10–12S III and IV generate trun-
cated Shank3 isoforms which only contain the ANK do-
main known to interact with cytoskeleton proteins such as
alpha-fodrin and sharpin [30,36]. Conceptually, these iso-
forms will compete with the binding of full-length Shank3
to alpha-fodrin and sharpin, thereby modulating the re-
arrangement of the PSD structure. It is interesting that
these isoforms are highly expressed at early stages of brain
development and concentrated in the olfactory bulb of
adult brain. The splicing variant E18S II showed similar
region- and development-specific splicing patterns to that
of E10–12S, implying that they may coordinate with each
other for some functions. Exon 18 inclusion may be consid-
ered a neuronal marker at the mRNA level, as it occurs
specifically in neurons, but not in astrocytes or peripheral
tissues [12]. Exon 18 contains 24 nucleotides that encode 8
amino acids containing an arginine stretch (RRRK) residues
that is similar to the "RXR" motif. It has been shown that
the RXR motif serves as an endoplasmic reticulum (ER)
retention signal in the NMDA receptor subunit NR1 [37].
Whether or not this motif regulates the sorting and traffick-
ing of Shank3 in vivo is an interesting question for further
investigation. Third, the functional diversity of Shank3
isoforms is supported by the finding that Shank3 isoforms
display different subcellular localization and differential
effects on spine morphology. For example, the full length
Shank3a increased the density of dendritic spines and
PDS-95 puncta, but Shank3b and Shank3e have an
opposite impact on dendritic spine development. The
nuclear targeting of Shank3b in heterologous cells and
neurons implicates that this isoform probably possesses
a function other than as a scaffolding protein at the PSD
as described to date. In addition, the temporally- and
regionally-specific expression of Shank3 isoforms also
supports the concept that different isoforms have differ-
ent functions. Altogether, our data strongly support a
notion that different Shank3 isoforms contribute differ-
entially to synaptic function. Follow-up studies arewarranted to determine the distinct role for each isoform
in synaptic development and function.
The complexity of Shank3 and the specification of synapses
Although the phenomena of alternative splicing and mul-
tiple promoters are commonly described in both neuronal
and non-neuronal genes, the degree of the complexity de-
scribed for Shank3 is somewhat unusual. A similar level or
even more complexity has been described for genes such as
Neurexin family proteins and Brain Derived Neurotrophic
Factor [38,39]. The exact number of Shank3 mRNAs and
protein isoforms is not known. Whether all mRNA iso-
forms are translated into proteins cannot be easily deter-
mined. Given the tissue-/cell-type and developmental-stage
specific promoter usage and alternative splicing, the num-
ber of Shank3 isoforms could be very substantial and
possibly reach to more than a hundred. The interesting
question is whether there is a biological purpose underlying
such complexity as has been observed for Shank3. Humans
have billions of neurons and a trillion synapses but a rela-
tively small number of genes in a genome (approximately
20,000). We have a limited understanding of what contrib-
utes to the diversity of synapses, and the current methods
to classify different types of synapses are extremely simpli-
fied. From revealing the complexity of Shank3 and other
synaptic proteins, one plausible hypothesis is that the myr-
iad isoforms of Shank3 and other synaptic proteins are des-
tined to contribute to the diversity or specification of types
of synapses. One could speculate that the different isoforms
of Shank3 may localize differentially in the nano-structure
of the PSD, such as central versus peripheral sites in the
PSD of the same synapse, or different isoforms of Shank3
are at different excitatory synapses in a given pyramidal
neuron. In addition, some protein isoforms may be present
only when the neurons are stimulated with certain types of
neural activity that lead to local protein translation for spe-
cific Shank3 mRNA isoforms. To examine these possibil-
ities, high resolution cellular imaging at single synapses is
required and isoform-specific antibodies will be helpful to
assist these analyses.
The complex Shank3 transcriptional regulation and
phenotypic heterogeneity of Shank3 mutant mice and
SHANK3 causing ASD
Considerable clinical heterogeneity in ASD has been well
documented [40-42], although the cause underlying this
heterogeneity remains largely unknown. Molecular hetero-
geneity due to the number of genes has been hypothesized
to be one of the logical explanations [43,44], and has been
supported by the findings of whole exome or whole gen-
ome sequencing of ASD cases [45-48]. However, in the
case of SHANK3 causing ASD, considerable heterogeneity
is also observed among the cases with different mutations
within the SHANK3 gene [8]. We have previously shown
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promoter usage and alternative splicing [25]. With the
knowledge of the complexity of Shank3 transcriptional
regulation reported here, the clinical heterogeneity of
SHANK3 causing ASD could be predicted to result from
the disruption of different sets of SHANK3 isoforms due
to the location of the mutation within the coding exons of
SHANK3. This prediction has been supported by Shank3-
isoform mutant mouse models, in which phenotypic diver-
sity was demonstrated among mutant mice with disruption
of different isoforms [16-20]. A striking example is that
disruption of Shank3a to Shank3c results in skin lesion/
increased self-grooming phenotype, but this phenotype is
absent in Shank3a to Shank3b deficient mice, implicating
the unique role of Shank3c in the development of self-
induced skin lesions. Although genetic background and en-
vironmental factors may also contribute to the phenotypic
heterogeneity in SHANK3 causing ASD and Shank3 mu-
tant mice, our analysis of Shank3 isoforms provides a
framework at the molecular level to understand the ques-
tion of phenotypic heterogeneity. A head-to-head compari-
son between different Shank3 mutant mice in the same
genetic background and in vivo analysis of the function of
each Shank3 isoform will yield insights into the mechanism
underlying phenotypic heterogeneity in SHANK3 causing
ASD.
Conclusions
In summary, we showed a complex transcriptional regu-
lation of Shank3 in mouse brain that resulted in diverse
Shank3 isoforms. The regional, developmental, activity-
dependent, and epigenetic modulation of isoform-specific
expression and alternative splicing of Shank3 suggest a dif-
ferent function for each Shank3 isoform. It is predicted
that the SHANK3 defects in reported ASD patients and
Shank3 mutant mice are isoform-specific. Our study then
provides a molecular framework to dissect clinical hetero-
geneity of SHANK3 causing human disorders and provide
insight to better understand the molecular basis under-
lying the clinical heterogeneity of ASD in general. In
addition, these findings are critically important to interpret
the difference between different lines of Shank3 mutant
mice and formulate the plan to further analyze these mu-
tant mice to elucidate the contribution of Shank3 to the
pathophysiology of ASD.
Additional files
Additional file 1: Table S1. List of Shank3 primers used in this study.
Additional file 2: Figure S1. Brain-specific expression of Shank3
intragenic promoters. (A) Shank3 gene structure. Intragenic promoters are
shown as black arrows. Exons in red are alternatively spliced exons. In lower
panel, positions of primers for Shank3 isoforms and splice variants used in
this study are indicated. Note that splicing forward primer (in red) for E18S isspecific for promoter 5. (B) The presence of multiple intragenic promoters
supported by in silico data from ENCODE project using mouse mm10
genome assembly (http://genomebrowser.wustl.edu/). The CHIP sequence
data using antibodies against RNA polymerase II (Pol II) and trimethylated
lysine 4 of histone 3 (H3K4me3), two landmarks for active promoters,
displayed several corresponding peaks (blue rectangular, dash line indicates
a weak promoter) near Shank3 promoters (arrows below Shank3 gene) in
brain tissues but not in heart and kidney, indicating these intragenic
promoters are brain specific. (C) Brain specific expression of Shank3 isoforms
from intragenic promoters. Left panel: Western blot analysis using a Shank3
antibody against C-terminus of SHANK3 (sc-30193, Santa Cruz, CA, USA)
revealed multiple bands across different tissues. The bands with predicted
size of Shank3c, 3d, and 3e are observed in cerebral cortex and cerebellum
but not in heart, liver, and kidney. Shank3b is not detectable because it does
not contain the C-terminal sequence of Shank3 protein. This result supports
that the intragenic promoters are brain-specific. Right panel: Ponceau S
staining of the PVDF membrane on the left panel to show that an equal
amount of protein (30 μg) was loaded to each lane. Note there is variation
of endogenous protein composition across different tissues.
Additional file 3: Figure S2. Extensive splicing of Shank3 mRNAs. (A–B)
Shank3 exons 10–12 spliced (E10–12S) variants. At least five different products
of E10–12S are identified by RT-PCR (A) and the sequences of E10–12S variants
were illustrated (B). Arrows indicate the position of primers. I: no splicing. II:
exon 11 partially spliced out. III: exon 11 spliced out. IV: exons 11 to 12 spliced
out. V: exons 10 to 12 spliced out. Note that regular PCR reactions yield mostly
spliced variants as the full-length of this sequence without alternative splicing
can only be amplified in GC-rich buffer due to the extremely high GC
percentage (79%) in exon 11 (see Materials and methods). (C–D) Shank3e
spliced variants (E18S). Different sets of primers yielded various PCR products
(C): left panel with primers 1 and 2, right panel with primers 1 and 3. The
forward primer 1 is specific for Shank3e isoforms from promoter 5. Gene
structure of full-length Shank3e and its spliced variants are illustrated in (D),
with arrows showing the position for primers. I: no splicing. II: exon 18 spliced
out. III: exons 18, 21, and 22 (partial) spliced out. IV: exons 18 to 21 and 22
(partial) spliced out. E–F, Splicing variants of Shank3 exon 21 and exon 22
(E21–22S). The PCR products are shown in (E), with left panel using primers 2
and 3, right panel using primers 1 and 3. Gene structure of exons 19–22 and
its splicing variants were illustrated in (F), with primers labeled as arrows. I: no
splicing. II: exon 22 partially spliced out. III: exon 21 spliced out. IV: exon 21 and
exon 22 (partial) spliced out. Gene bank accession numbers are shown in red
for novel splicing variants identified by the current study. Accession numbers in
black are splicing variants identified in the previous study by Wang et al. [18].
Additional file 4: Figure S3. Differential expression and alternative
splicing of Shank3 isoforms in neurons and astrocytes. mRNAs from
cultured hippocampal neurons and astrocytes were analyzed by RT-PCR.
All major isoforms of Shank3 mRNAs were expressed abundantly in
neurons as expected. Shank3a, 3c, 3d, 3e, and 3e-1 were low but readily
detectable in astrocytes. Alternative splicing of exon 18 was mutually
exclusive between cell types, with exon18 inclusion (E18S I) in neurons
and exon18 exclusion (E18S II) in astrocytes. Similarly, the E18S III variant
was exclusively observed in neurons while E18S IV was only found in
astrocytes. N, neuron. A, astrocyte.
Additional file 5: Figure S4. Differentiated cellular distribution of
Shank3 isoforms. Shank3 isoforms tagged with GFP (green) were
expressed in COS-7 cells (A) or primary hippocampal neurons (B). Cells
were co-stained with 4′,6-diamidino-2-phenylindole (DAPI) to label the
nuclei (blue). PSD-95 antibody was employed to distinguish hippocampal
neurons. Note that Shank3b localizes in nuclei in both COS-7 cells and
hippocampal neurons. Shank3 E22: EGFP-Shank3 exon 22 that only
encodes SAM domain. Scale bar: 10 μm.
Additional file 6: Figure S5. Shank3 isoforms are not localized in
inhibitory synapses. Shank3 isoforms tagged with GFP (green) were
expressed in primary hippocampal neurons and co-stained with an
inhibitory post-synaptic marker Gephyrin (red). Note that there is no
overlapping of Gephyrin with Shank3 isoforms. Scale bar: 10 μm.
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